Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
Public ClinicalTrials.gov record NCT02732938. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PHASE 1B/2 STUDY OF PF-04136309 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase 1b/2 study is to evaluate the safety and tolerability of PF-04136309 in combination with nab-paclitaxel and gemcitabine, characterize the dose-limiting toxicities (DLTs) and overall safety profile of escalated doses of PF-04136309 and the associated schedule, determine the maximum tolerated dose (MTD), and to assess the enhancement of efficacy of PF-04136309 in combination with nab-paclitaxel and gemcitabine versus nab-paclitaxel + gemcitabine + placebo in terms of Progression Free Survival.
Study identification
- NCT ID
- NCT02732938
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 4, 2016 (Actual)
- Primary completion
- Sep 15, 2017 (Actual)
- Completion
- Oct 10, 2017 (Actual)
- Last update posted
- Feb 4, 2019
2016 – 2017
United States locations
- U.S. sites
- 18
- U.S. states
- 4
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10022 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of Rochester Cancer Center Pharmacy | Rochester | New York | 14642 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Sampson Regional Medical Center | Clinton | North Carolina | 28328 | — |
| Southeastern Medical Oncology Center | Clinton | North Carolina | 28328 | — |
| Southeastern Medical Oncology Center | Goldsboro | North Carolina | 27534 | — |
| Wayne Memorial Hospital | Goldsboro | North Carolina | 27534 | — |
| Onslow Memorial Hospital | Jacksonville | North Carolina | 28546 | — |
| Southeastern Medical Oncology Center | Jacksonville | North Carolina | 28546 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| MUSC Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| MUSC Health East Cooper | Mt. Pleasant | South Carolina | 29464 | — |
| MUSC Health North Charleston | North Charleston | South Carolina | 29406 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02732938, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2019 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02732938 live on ClinicalTrials.gov.